RioCard-001 is under clinical development by Rion and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase II drugs for Myocardial Infarction have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RioCard-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RioCard-001 overview
RioCard-001 is under development for the treatment of acute myocardial infarction. It is administered through intra-arterial route. The therapeutic candidate comprises of purified exosome product (PEP).
Rion overview
Rion is a clinical-stage biotechnology company. It focuses on developing exosome therapies. The company’s product pipeline includes therapies for the treatment of acute myocardial infarction, female stress urinary incontinence, musculoskeletal and wound healing. It develops Purified Exosome Product (PEP), an innovative biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine. Rion is headquartered in Rochester, Minnesota, the US.
For a complete picture of RioCard-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.